Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
08/2000
08/22/2000US6107323 Preventing or treating angiotensin diseases by administering an antagonist and compound which increases insulin sensitivity
08/22/2000US6107291 Antiinflammatory agent
08/22/2000US6107289 Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
08/22/2000US6106826 Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
08/17/2000WO2000047729A1 Deglycosylated kringle 1-5 region fragments of plasminogen and methods of use
08/17/2000WO2000047624A1 Dihydroouabain-like factor and diagnostic and therapeutic compositions and methods
08/17/2000WO2000047623A1 Artificial peptides having surface activity and the use thereof in the preparation of artificial surfactant
08/17/2000WO2000047619A1 Therapeutics and diagnostics based on an il-1b mutation
08/17/2000WO2000047602A1 33 human secreted proteins
08/17/2000WO2000047583A1 Cyclic substituted fused pyrrolocarbazoles and isoindolones
08/17/2000WO2000047565A1 Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases
08/17/2000WO2000047564A1 Novel guanidine derivatives as inhibitors of cell adhesion
08/17/2000WO2000047562A1 Spirocyclic ketones and their use as tachykinin antagonists
08/17/2000WO2000047238A1 Integration of transplanted neural progenitor cells into neural tissue of immature and mature dystrophic recipients
08/17/2000WO2000047212A1 Quinazoline derivatives as angiogenesis inhibitors
08/17/2000WO2000047195A1 Stimulating neutrophil function to treat inflammatory bowel disease
08/17/2000WO2000033837A3 Myt1 kinase inhibitors
08/17/2000WO2000027819A3 Antrhranilic acid amides and the use thereof as medicaments
08/17/2000WO2000012076A9 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
08/17/2000WO2000009109A3 Pipecolic acid derivatives for vision and memory disorders
08/17/2000CA2367575A1 Stimulating neutrophil function to treat inflammatory bowel disease
08/17/2000CA2362272A1 Spirocyclic ketones and their use as tachykinin antagonists
08/17/2000CA2361334A1 Deglycosylated kringle 1-3 region fragments of plasminogen and methods of use
08/17/2000CA2361293A1 33 human secreted proteins
08/16/2000EP1028114A1 Novel guanidine derivatives as inhibitors of cell adhesion
08/16/2000EP1027332A1 Novel lactam metalloprotease inhibitors
08/16/2000EP1027065A1 Method for destroying retinal pigment epithelial cells
08/16/2000EP1027016A1 Methods and pharmaceutical compositions for the closure of retinal breaks
08/16/2000CN1263087A Substituted alkyl tetramine derivative
08/16/2000CN1262933A Soluble granules for curing vitreous opacity and vitreous hemorrhage and preparation method thereof
08/16/2000CN1055399C Acupoint application liquid for myopia
08/15/2000US6103762 A biaromatic compounds in which the aromatic nuclei are connected by a propynylene or allenylene divalent radical, useful as human or veterinary medicine or used in cosmetics or keratinization disorders
08/15/2000US6103739 Metalloproteinase inhibitors
08/15/2000US6103507 Protein used to raise an immunological response against a bacteria; bactericides
08/15/2000CA2136553C 7-(2-aminoethyl)-benzothiazolones
08/10/2000WO2000046253A1 Process for the production of multiple cross-linked hyaluronic acid derivatives
08/10/2000WO2000046252A1 Process for cross-linking hyaluronic acid to polymers
08/10/2000WO2000046221A1 Sulfamato hydroxamic acid metalloprotease inhibitor
08/10/2000WO2000046215A1 Benzazepine derivatives as alpha-v integrin receptor antagonists
08/10/2000WO2000045835A1 Vascular endothelial growth factor-2
08/10/2000WO2000045818A1 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
08/10/2000WO2000027822A3 Tricyclic pyrazole derivatives
08/10/2000WO2000027424A3 Upregulation of endogenous prostaglandins to lower intraocular pressure
08/10/2000WO2000024359A3 Use of gndf for treating retinal degeneration
08/10/2000WO2000015206A3 Tryptophanyl ester and their n-acyl derivatives for the prevention and treatment of diseases caused or exacerbated by oxidation processes
08/10/2000WO1999063936A9 Novel therapeutic agents that modulate endothelin receptors
08/10/2000CA2362230A1 Sulfamato hydroxamic acid metalloprotease inhibitor
08/10/2000CA2361615A1 The use of vascular endothelial growth factor 2 antagonist in the treatment of an injury to or disorder of an eye
08/10/2000CA2358855A1 Benzazepine derivatives as alpha-v integrin receptor antagonists
08/09/2000EP1026147A1 Compounds useful as intermediates in the production of piperidine derivatives
08/09/2000EP1025106A2 Allosteric adenosine receptor modulators
08/09/2000EP1025079A1 $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
08/09/2000EP1024814A2 Use of antifungal agents for the topical treatment of fungus-induced mucositis
08/09/2000EP1024810A1 Method for optimizing retinal and optic nerve health
08/09/2000CN1262624A Use of colchinol derivatives as vascular damaging agents
08/09/2000CN1262623A Prostaglandin derivatives devoid of side-effects for treatment of glaucoma
08/09/2000CN1055247C External-use medicine for treating myopia
08/08/2000US6100282 Thiazole derivatives
08/08/2000US6100266 Hydroxamic and carboxylic acid derivatives
08/08/2000US6099823 Compositions and methods for the treatment and diagnosis of cardiovascular disease
08/08/2000CA2187402C Quinoxaline derivatives for treating tinnitus
08/08/2000CA2185512C Treatment of tinnitus using neuroprotective agents
08/08/2000CA2185019C Isoxazoline compounds as inhibitors of tnf release
08/08/2000CA2018438C Imidazolyl-alkenoic acids
08/03/2000WO2000044786A1 Novel potassium channels and genes encoding these potassium channels
08/03/2000WO2000044761A2 Ketolide antibiotics
08/03/2000WO2000044740A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000WO2000044739A1 Reverse hydroxamate inhibitors of matrix metalloproteinases
08/03/2000WO2000044733A1 Peptidyl heterocyclic ketones useful as tryptase inhibitors
08/03/2000WO2000044730A1 2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
08/03/2000WO2000044711A1 ACETYLENIC $G(b)-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID TACE INHIBITORS
08/03/2000WO2000044710A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000WO2000044397A2 Growth of inner ear and monoclonal antibody against utricular epithelium
08/03/2000WO2000044391A2 Plasminogen kringle 4 region fragments and methods of use
08/03/2000WO2000044383A1 Anti-inflammatory agents and inhibitors against increase in ocular tension caused by irradiation with lasers, containing 1,4-dihydropyridine derivatives
08/03/2000WO2000044379A2 Methods for restoring and/or enhancing accommodation in pseudo phakia
08/03/2000WO2000044375A1 Antioxidant compositions and methods for companion animals
08/03/2000WO2000044371A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
08/03/2000WO2000044350A1 Transnasal transport/immunisation with highly adaptable carriers
08/03/2000WO2000038714A8 The prevention and treatment of retinal ischemia and edema
08/03/2000WO2000032175A3 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY
08/03/2000WO2000024415A3 Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
08/03/2000WO2000020421A3 TRICYCLIC Δ3-PIPERIDINES AS α2-ANTAGONISTS
08/03/2000WO2000009102A9 Carboxylic acids and isosteres of n-heterocyclic compounds for vision and memory disorders
08/03/2000WO1999026942A8 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
08/03/2000DE19901921A1 Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels Polymorphs of telmisartan, to processes for their preparation and their use for the preparation of a medicament
08/03/2000CA2361479A1 Peptidyl heterocyclic ketones useful as tryptase inhibitors
08/03/2000CA2360690A1 Plasminogen kringle 4 region fragments and methods of use
08/03/2000CA2360689A1 Anti-inflammatory agents and inhibitors against increase in ocular tension caused by irradiation with lasers, containing 1,4-dihydropyridine derivatives
08/03/2000CA2360674A1 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
08/03/2000CA2360643A1 Transnasal transport/immunisation with highly adaptable carriers
08/03/2000CA2356855A1 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356481A1 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356345A1 Acetylenic beta-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
08/03/2000CA2356313A1 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors
08/03/2000CA2356267A1 2,3,4,5-tetrahydro-1h-¬1,4|benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
08/02/2000EP1023904A2 Adjuvants for use in vaccines
08/02/2000EP1023322A1 Novel npy family member
08/02/2000EP1023081A1 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
08/02/2000EP1023077A1 Opthalmic composition
1 ... 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 ... 531